Not much new in Mayo Geron article: Needham

|About: Geron Corporation (GERN)|By:, SA News Editor

Needham's Chad Messer doesn't see "a whole lot that is new" in the Mayo Clinic article highlighting Geron's (GERN +8.7%) imetelstat.

"We remain positively inclined towards the data but feel investors should wait for full presentation, as well as GERN's investor event, on Monday to understand the full story," Messer adds.